HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia

Achieving a deep molecular response (DMR) to tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML) remains challenging and at present, there is no biomarker to predict DMR in this setting. Herein, we report that an HMGCLL1 genetic variant located in 6p12.1 can be used as a predi...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jong-Ho, Woo, Young Min, Youm, Emilia Moonkyung, Hamad, Nada, Won, Hong-Hee, Naka, Kazuhito, Park, Eun-Ju, Park, June-Hee, Kim, Hee-Jin, Kim, Sun-Hee, Kim, Hyeoung-Joon, Ahn, Jae Sook, Sohn, Sang Kyun, Moon, Joon Ho, Jung, Chul Won, Park, Silvia, Lipton, Jeffrey H., Kimura, Shinya, Kim, Jong-Won, Kim, Dennis (Dong Hwan)
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756062/
https://www.ncbi.nlm.nih.gov/pubmed/30555164
http://dx.doi.org/10.1038/s41375-018-0321-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756062/
https://www.ncbi.nlm.nih.gov/pubmed/30555164
http://dx.doi.org/10.1038/s41375-018-0321-8

Ejemplares similares